Diffusion Pharmaceuticals Inc. – NASDAQ:DFFN

Add to watchlist

Market open

Closed in 3 minutes

+42.47%

month

+96.28%

quarter

+31.54%

year

Market Cap	8.97M
Enterprise value	N/A

P/E	-0.55
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	0.41
PEG ratio	-0.01
EPS	-6149.37

Revenue	N/A
EBITDA	-13.48M
Income	-8.36B
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN): Profit margin
Dec 2022	0	2.02M
Mar 2023	0	-8.36B
Jun 2023	0	-2.11M
Sep 2023	0	2.15M

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN): Debt to assets
Dec 2022	22635052	2.41M	10.68%
Mar 2023	18404886	2.12M	11.55%
Jun 2023	15694618	1.46M	9.33%
Sep 2023	12037863	2.46M	20.47%

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN): Cash Flow
Dec 2022	-3.47M	7M	5K
Mar 2023	-4.96M	9.5M	0
Jun 2023	-2.64M	3M	0
Sep 2023	2.25M	0	6.98M

Diffusion Pharmaceuticals alternative data

Diffusion Pharmaceuticals
Employees

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN): Employee count
Aug 2023	13
Sep 2023	13
Oct 2023	13
Nov 2023	13
Dec 2023	13
Jan 2024	13
Feb 2024	13
Mar 2024	13
Apr 2024	13
May 2024	13
Jun 2024	13
Jul 2024	13

Diffusion Pharmaceuticals
Hedge Funds Holdings Q1 2023

100.00% 0.00%

of DFFN is owned by hedge funds

7 -5

hedge funds hold DFFN stock

76.38K -106.11K

shares is hold by hedge funds

DFFN hedge funds holdings changes

Diffusion Pharmaceuticals
Insider Trading

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN): Insider trades (number of shares)
Period	Buy	Sel
May 2021	32786	0
Mar 2022	10000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	31 Aug 2023	HOLLINGSWORTH JANE H director director	Common Stock	122	$266.4	$32,501
Option	31 Aug 2023	HOLLINGSWORTH JANE H director director	Restricted Stock Unit	122	N/A	N/A
Option	30 Jun 2023	LANCHONEY DIANA M director director	Restricted Stock Unit	232	N/A	N/A
Option	30 Jun 2023	LANCHONEY DIANA M director director	Common Stock	232	$283.9	$65,865
Option	31 May 2023	HOLLINGSWORTH JANE H director director	Common Stock	183	$263.84	$48,283
Option	31 May 2023	HOLLINGSWORTH JANE H director director	Restricted Stock Unit	183	N/A	N/A
Option	31 Mar 2023	LANCHONEY DIANA M director director	Common Stock	232	$352.75	$81,838
Option	31 Mar 2023	LANCHONEY DIANA M director director	Restricted Stock Unit	232	N/A	N/A
Option	28 Feb 2023	HOLLINGSWORTH JANE H director director	Restricted Stock Unit	183	N/A	N/A
Option	28 Feb 2023	HOLLINGSWORTH JANE H director director	Common Stock	183	$391	$71,553

DFFN insider trading transactions

Diffusion Pharmaceuticals
Executives

Insider	Age	Compensation
Dr. Robert J. Cobuzzi Jr. (1965) Pres, Chief Executive Officer & Director	60	$536,940
Mr. William Karl Hornung (1969) Chief Financial Officer	56	$409,870
Dr. Christopher D. Galloway M.D. (1971) Chief Medical Officer	54	$373,490
Mr. William Robert Elder J.D. (1983) Gen. Counsel & Corporation Sec.	42	$300,570

Diffusion Pharmaceuticals
Latest News

Wednesday, 16 August 2023
13:58	CervoMed Announces Completion of Merger with EIP Pharma	prnewswire.com
Tuesday, 15 August 2023
16:01	Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma	globenewswire.com
Monday, 3 April 2023
14:13	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, LSI, EXR, DFFN	prnewswire.com
Friday, 31 March 2023
20:01	DIFFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Diffusion Pharmaceuticals Inc. - DFFN	businesswire.com
Thursday, 30 March 2023
10:42	DFFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Diffusion Pharmaceuticals Inc. Is Fair to Shareholders	businesswire.com
Tuesday, 17 May 2022
07:30	Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference	GlobeNewsWire
Tuesday, 19 April 2022
18:01	5 Stocks Halted In Tuesday's Session	Benzinga
Monday, 18 April 2022
20:28	Diffusion Pharmaceuticals (DFFN) Stock: 1-For-50 Reverse Stock Split Announced	Pulse2
10:52	Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow	Benzinga
09:48	Why Diffusion Pharmaceuticals Shares Are Falling	Benzinga
Monday, 20 December 2021
07:02	Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P.	GlobeNewsWire
Wednesday, 1 December 2021
13:51	Diffusion Pharmaceuticals (DFFN) Stock: Why The Price Increased Today	Pulse2
Monday, 29 November 2021
13:14	Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility	PennyStocks
Thursday, 14 October 2021
09:25	7 Biotech Penny Stocks With Huge Catalysts Coming in 2022	InvestorPlace
Thursday, 9 September 2021
07:32	Diffusion Pharmaceuticals Issues Letter to Shareholders	GlobeNewsWire
Wednesday, 8 September 2021
07:32	Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference	GlobeNewsWire
Monday, 30 August 2021
09:15	DFFN Stock: Over 7% Increase Pre-Market Explanation	Pulse2
07:32	Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA's Pulmonology, Allergy, and Critical Care Division	GlobeNewsWire

Frequently Asked Questions (FAQ)

When is Diffusion Pharmaceuticals's next earnings date?

Unfortunately, Diffusion Pharmaceuticals's (DFFN) next earnings date is currently unknown.
Does Diffusion Pharmaceuticals pay dividends?

No, Diffusion Pharmaceuticals does not pay dividends.
How much money does Diffusion Pharmaceuticals make?

Diffusion Pharmaceuticals has a market capitalization of 8.97M.
What is Diffusion Pharmaceuticals's stock symbol?

Diffusion Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "DFFN".
What is Diffusion Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Diffusion Pharmaceuticals?

Shares of Diffusion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Diffusion Pharmaceuticals's key executives?
Diffusion Pharmaceuticals's management team includes the following people:
- Dr. Robert J. Cobuzzi Jr. Pres, Chief Executive Officer & Director(age: 60, pay: $536,940)
- Mr. William Karl Hornung Chief Financial Officer(age: 56, pay: $409,870)
- Dr. Christopher D. Galloway M.D. Chief Medical Officer(age: 54, pay: $373,490)
- Mr. William Robert Elder J.D. Gen. Counsel & Corporation Sec.(age: 42, pay: $300,570)
How many employees does Diffusion Pharmaceuticals have?

As Jul 2024, Diffusion Pharmaceuticals employs 13 workers.
When Diffusion Pharmaceuticals went public?

Diffusion Pharmaceuticals Inc. is publicly traded company for more then 17 years since IPO on 23 May 2008.
What is Diffusion Pharmaceuticals's official website?

The official website for Diffusion Pharmaceuticals is diffusionpharma.com.
Where are Diffusion Pharmaceuticals's headquarters?

Diffusion Pharmaceuticals is headquartered at 300 East Main Street, Charlottesville, VA.
How can i contact Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals's mailing address is 300 East Main Street, Charlottesville, VA and company can be reached via phone at +43 4220 0718.

Diffusion Pharmaceuticals Inc.

diffusionpharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

+43 4220 0718

300 East Main Street
Charlottesville, VA 22902

CIK: 0001053691
ISIN: US15713L1098
CUSIP: 253748305